Masavibart (ZRC3308-A7), an IgG1 type anti-SARS-CoV-2 monoclonal antibody, demonstrates strong binding affinity for a distinct non-competing epitope located on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. When paired in a 1:1 ratio with ZRC3308-B10, Masavibart is efficacious in preventing COVID-19, particularly in its early stages before the onset of severe symptoms [1].